Lycorine 石蒜碱|cas:476-28-8|西域试剂

Lycorine 石蒜碱,98.89%

产品编号：Bellancom-N0288| CAS NO：476-28-8| 分子式：C₁₆H₁₇NO₄| 分子量：287.31

Lycorine 是从金眼科植物科中提取的天然生物碱，具有抗病毒，抗疟疾和抗发炎的活性。Lycorine 抑制激素难治性抗前列腺癌 (PCa) 的生长和转移并诱导细胞凋亡 (apoptosis)。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-N0288		￥800.00	杭州北京（现货）
Bellancom-N0288		￥1300.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Lycorine 石蒜碱

产品介绍

Lycorine 是从石蒜科植物中提取的天然生物碱。Lycorine 是强效具有口服活性的 SCAP 抑制剂，K_d 值 15.24 nM。Lycorine 下调 SCAP 蛋白水平而不改变其转录。Lycorine 也是黑色素瘤血管生成抑制剂。Lycorine 有潜力用于前列腺癌和代谢疾病的研究。

生物活性

Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a K_d value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription. Lycorine is also a melanoma vasculogenic inhibitor. Lycorine can be used for the study of prostate cancer and metabolic diseases.

体外研究

Lycorine inhibits cell proliferation in a dose-dependent manner in the abovementioned 4 PCa cell lines, and the IC₅₀ ranged from 5 μM to 10 μM., it also shows Lycorine has little effects on PNT1A cell's proliferation.
SCAP (SREBF chaperone) is an ER-toGolgi transport protein, undergoes a conformational change, and regulates/preserves SREBFs in the ER by forming a complex with INSIG1 (insulin induced gene 1).
Lycorine (5-40 μM; 16 hours) significantly suppresses SREBFs activity (up to -70%) in a dosedependent manner and does not cause obvious cytotoxicity in cells.
Lycorine (10-20 μM; 2-16 hours) dose- and time-dependently decreases the mature SREBF1 and SREBF2 proteins in HL-7702 cells.
Lycorine (20 μM; 16 hours) neither activates NR1H3 transcription nor affect NR1H3 target genes, including ABCG5 and ABCG8, but Sterols activates NR1H3 transcription activity.
Lycorine hydrochloride (0-25 μM; 48 hours) treatment markedly suppresses the expression of vascular endothelial (VE)-cadherin in a dose-dependent manner and also slightly diminishes the expression of Sema4D in C8161 cells. However, the expression of the other six genes is not affected.
Lycorine hydrochloride (0-25 μM; 48 hours) treatment markedly reduces VE-cadherin protein levels in C8161 cells in a dose-dependent fashion.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HL-7702/SRE-Luc cells
Concentration:	16 hours
Incubation Time:	5 μM; 10 μM; 20 μM; 40 μM
Result:	Had no cytotoxicity on HL-7702 cells.

Western Blot Analysis

Cell Line:	HL-7702/SRE-Luc cells
Concentration:	2 hours, 4 hours, 8 hours, 12 hours, 16 hours
Incubation Time:	10 μM; 20 μM
Result:	Decreased p-SREBF1, m-SREBF1, p-SREBF2 and p-SREBF1 protein expression.

RT-PCR

Cell Line:	C8161 cells
Concentration:	0 μM, 1.56 μM, 3.13 μM, 6.25 μM, 12.5 μM, 25 μM
Incubation Time:	48 hours
Result:	Markedly suppressed the expression of VE-cadherin in a dose-dependent manner and also slightly diminished the expression of Sema4D in C8161 cells.

体内研究
(In Vivo)

Lycorine (oral chow; 15 mg/kg, 30 mg/kg; once daily) alleviates fat accumulation and metabolic syndrome, increases lipolysis and betaoxidation of fatty acid along with precursor and mature SREBFs in mice .

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	High-fat diet (HFD)-fed C57BL/6J mice
Dosage:	15 mg/kg, 30 mg/kg
Administration:	Oral chow; once daily
Result:	Ameliorated high-fat diet-induced hyperlipidemia, hepatic steatosis, and insulin resistance in mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	High-fat diet (HFD)-fed C57BL/6J mice
Dosage:	15 mg/kg, 30 mg/kg
Administration:	Oral chow; once daily
Result:	Ameliorated high-fat diet-induced hyperlipidemia, hepatic steatosis, and insulin resistance in mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	High-fat diet (HFD)-fed C57BL/6J mice
Dosage:	15 mg/kg, 30 mg/kg
Administration:	Oral chow; once daily
Result:	Ameliorated high-fat diet-induced hyperlipidemia, hepatic steatosis, and insulin resistance in mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (87.01 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4806 mL	17.4028 mL	34.8056 mL
5 mM	0.6961 mL	3.4806 mL	6.9611 mL
10 mM	0.3481 mL	1.7403 mL	3.4806 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Hu M, et al.Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.Oncotarget. 2015 Jun 20;6(17):15348-61.

. Zu-Guo Zheng, et al. Discovery of a Potent SCAP Degrader That Ameliorates HFD-induced Obesity, Hyperlipidemia and Insulin Resistance via an Autophagy-Independent Lysosomal Pathway. Autophagy. 2020 May 20;1-22. [Content Brief]

. .Liu, R. et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment cell & melanoma research 25, 630-638, doi:10.1111/j.1755-148X.2012.01036.x (2012). [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

危害码 (欧洲)	T: Toxic;
风险声明 (欧洲)	R25
安全声明 (欧洲)	45
危险品运输编码	UN 2811 6.1/PG 3
WGK德国	3

1. 物质的识别

产品名：	Lycorine
CAS号：	476-28-8
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Lycorine
分子式：
分子量：	287.31

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。